Comparative Preclinical Pharmacokinetic and Metabolic Studies of the Combretastatin Prodrugs Combretastatin A4 Phosphate and A1 Phosphate

Clinical Cancer Research

Volumn 10, Issue 4, 2004, Pages 1446-1453

  Kirwan, Ian G ^a,b   Loadman, Paul M ^a   Swaine, David J ^a   Anthoney, D Alan ^a,b   Pettit, George R ^c   Lippert III, John W ^c   Shnyder, Steve D ^a   Cooper, Patricia A ^a   Bibby, Mike C ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; COMBRETASTATIN; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; PRODRUG; TUBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CALIBRATION; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; INJECTION; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BIBENZYLS; CALIBRATION; CELL LINE, TUMOR; CHROMATOGRAPHY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORING AGENTS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MASS SPECTROMETRY; MICE; MODELS, CHEMICAL; PHOSPHORYLATION; PRODRUGS; STILBENES; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS;

EID: 1642283508     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0518-03     Document Type: Article

References (23)

1. Pettit, G. R., Singh, S. B., Niven, M. L., Hamel, E., and Schmidt, J. M. Antineoplastic agents 124. Isolation, structure, and synthesis of combretastatin-a-1 and combretasatin-B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J. Natural Products, 50: 119-131, 1987.
2. Pettit, G. R., Singh, S. B., Hamel, E., Lin, C. M., Alberts, D. S., and Garciakendall, D. Antineoplastic agents 145. Isolation and structure of the strong cell-growth and tubulin inhibitor combretastatin-a-4. Experientia (Basel), 45: 209-211, 1989.
3. Lin, C. M., Singh, S. B., Chu, P. S., Dempcy, R. O., Schmidt, J. M., Pettit, G. R., et al. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol. Pharmacol., 34: 200-208, 1988.
4. Pettit, G. R., and Lippert, J. W. Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs. Anti-Cancer Drug Des., 15: 203-216, 2000.
5. McGown, A. T., and Fox, B. W. Structural and biochemical-comparison of the anti-mitotic agents colchicine, combretastatin-A4 and amphethinile. Anti-Cancer Drug Des., 3: 249-254, 1989.
6. Pettit, G. R., Temple, C., Narayanan, V. L., Varma, R., Simpson, M. J., Boyd, M. R., et al. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anti-Cancer Drug Des., 10: 299-309, 1995.
7. Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., and Chaplin, D. J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res., 57: 1829-1834, 1997.
8. Grosios, K., Holwell, S. E., McGown, A. T., Pettit, G. R., and Bibby, M. C. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. J. Cancer, 81: 1318-1327, 1999.
9. Dowlati, A., Robertson, K., Cooney, M., Petros, W. P., Stratford, M., Jesberger, J., et al. A Phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res., 62: 3408-3416, 2002.
10. Remick, S., Robertson, K., Dowlati, A., Cooney, M., Jesberger, J., Lewin, J., et al. A Phase I pharmacokinetic (PK) study of single dose intravenous (IV) combretastatin A4 phosphate (CA4P) in patients (PTS) with advanced cancer: final report. Clin. Cancer Res., 7 (Suppl.): 393, 2001.
11. Galbraith, S. M., Taylor, N. J., Maxwell, R. J., Lodge, M., Tozer, G. M., Baddeley, H., et al. Combretastatin A4 phosphate (CA4P) targets vasculature in animal and human tumours. Br. J. Cancer, 83 (Suppl. 1): 12, 2000.
12. Chaplin, D. J., Pettit, G. R., and Hill, S. A. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res., 19: 189-195, 1999.
13. Grosios, K., Loadman, P. M., Swaine, D. J., Pettit, G. R., and Bibby, M. C. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res., 20: 229-233, 2000.
14. Murata, R., Siemann, D. W., Overgaard, J., and Horsman, M. R. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother. Oncol., 60: 155-161, 2001.
15. Nelkin, B. D., and Ball, D. W. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol. Rep., 8: 157-160, 2001.
16. Holwell, S. E., Cooper, P. A., Grosios, K., Lippert, J. W., Pettit, G. R., Shnyder, S. D., et al. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo antivascular effects in experimental tumours. Anticancer Res., 22: 707-711, 2002.
17. Hill, S. A., Tozer, G. M., Pettit, G. R., and Chaplin, D. J. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent oxi 4503. Anticancer Res., 22: 1453-1458, 2002.
18. Holwell, S. E., Cooper, P. A., Thompson, M. J., Pettit, G. R., Lippert, J. W., Martin, S. W., et al. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate. Anticancer Res., 22: 3933-3940, 2002.
19. Pettit, G. R., and Rhodes, M. R. Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. Anti-Cancer Drug Des., 13: 183-191, 1998.
20. UKCCCR Guidelines for the Welfare of Animals in Experimental Neoplasia. Br. J. Cancer, 77: 1-10, 1998.
21. Double, J. A., Ball, C. R., and Cowen, P. N. Transplantation of adenocarcinomas of the colon in mice. J. Natl. Cancer Inst. (Bethesda), 54: 271-275, 1975.
22. Mosman, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
23. Pettit, G. R., Lippert, J. W., Herald, D. L., Hamel, E., and Pettit, R. K. Antineoplastic agents 440. Asymmetric synthesis and evaluation of the combretastatin A-1 SAR probes (1S,2S)- and (1R,2R)-1,2-dihydroxy-1-(2′ ,3′-dihydroxy-4′-methoxyphenyl)-2-(3″,4″, 5″-trimethoxyphenyl)-ethane. J. Natural Products, 63: 969-974, 2000.